Developer docs
API playgroundTry for free, no card

Search company profiles

Epitel

Full company profile

uuid0000wlb

Namestring
Epitel
Legal namestring
Epitel, Inc.
Websiteurl
epitel.com
Company typeenum
Private
Founded yearint
2014
Descriptiontext

Epitel is a privately held digital health company headquartered in Salt Lake City, Utah, that develops wireless EEG (electroencephalography) monitoring systems for seizure detection in neurological care. The company's core product, the REMI Remote EEG Monitoring System, is a truly wireless, wearable platform consisting of four single-use, disposable sensors with eight electrodes forming a 10-channel montage, capable of continuous EEG capture for up to 30 days in both hospital and ambulatory settings. REMI is FDA-cleared for adult and pediatric patients (1+ years) and transmits data through REMI Mobile software to a secure REMI Cloud for review on Persyst Mobile, the dominant EEG viewing platform used by neurologists.

The company's AI offering, REMI Vigilenz AI for Event Detection, is an FDA-cleared software module (2024) that automatically identifies potential electrographic seizure activity in REMI EEG recordings and annotates detected events with tiered confidence levels (Very High 95-100% through Low 0-49%). The model was trained on a clinical validation dataset of 50 patient records covering over 2,600 hours of EEG activity and 87 known seizures, achieving 86.2% event-level sensitivity and 0.162 false alarms per hour in validation. The company holds 11 active US patents covering both REMI and a secondary Epilog sensor product line, and operates with SOC 2 Type 2 + HIPAA + GDPR compliance.

Epitel generates revenue through a combination of hardware sales (single-use disposable sensors) and recurring subscription software (REMI Vigilenz AI), with the system reimbursable via preexisting codes. The company targets emergency rooms, intensive care units, and hospitals for rapid EEG initiation in critical care use cases, and ambulatory/outpatient settings for extended seizure monitoring (addressing the limitations of traditional 72-hour wired EEG). The company sells directly to healthcare facilities through enterprise sales and has raised approximately $15.6 million in venture capital ($12.5M Series A in February 2022 plus a ~$3.12M exempt offering in March 2025), with notable investors including Genoa Ventures, Catalyst Health Ventures, OSF Ventures, Dexcom Ventures, MedMountain Ventures, SLC Angels, and Wavemaker 360 Health. Earlier funding included NIH grants totaling approximately $7.8 million and a $100,000 Ideaship investment.

Short descriptiontext

Epitel is a privately held digital health company that develops the REMI wireless EEG monitoring system and REMI Vigilenz AI for seizure detection, serving emergency rooms, ICUs, hospitals, and ambulatory patients in the U.S. neurology market.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSalt Lake City, United States
HQ citystring
Salt Lake City
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
wireless EEG monitoring, seizure detection devices, wearable neurological sensors, medical device AI, ambulatory EEG systems
Industry3 codes
PRIMARYHLAHACAE
Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
SECONDARYHLALAGAC
Neurology Telemedicine Platforms
Healthcare & Life Sciences/Telehealth Platforms/Specialty Telemedicine Platforms (e.g., dermatology, cardiology, neurology)
SECONDARYHLACAPAI
Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
NAICS code2 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing3345
SIC code1 code
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Neurological Monitoring Devices
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1REMI EEG Monitoring System
TypeHardware Sales
Description

Sale of wireless EEG monitoring system including sensors and software. Sensors are single-use, disposable, and wearable. The system is reimbursable using preexisting codes.

epitel.com
2REMI Vigilenz AI Software
TypeSubscription Recurring
Description

AI-powered event detection software for EEG analysis. FDA-cleared as medical device software that provides notifications to medical professionals.

epitel.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1REMI
Description

Wireless EEG monitoring system for seizure detection in healthcare facilities and ambulatory settings

epitel.com
+2 more records
Core offering1 text field

Epitel designs, manufactures, and sells the REMI Remote EEG Monitoring System, a truly wireless wearable EEG platform consisting of 4 single-use disposable sensors that capture brain electrical activity and wirelessly transmit data via the REMI Mobile app and REMI Cloud. The system is FDA-cleared for use in both healthcare facilities (hospitals, ERs, ICUs) and ambulatory settings in adult and pediatric patients (1+ years), supporting monitoring for up to 30 days. The company also offers REMI Vigilenz AI for Event Detection, an FDA-cleared AI software module that automatically identifies potential electrographic seizure activity within EEG recordings and provides tiered confidence-level annotations.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 86.2% event-level sensitivity and 0.162 false alarms per hour in clinical validation
+3 more records
Product overview1 text field

Epitel offers a wireless EEG monitoring platform centered on the REMI Remote EEG Monitoring System, a truly wireless wearable solution for seizure detection. The core REMI system consists of 4 disposable sensors with 8 electrodes creating a 10-channel montage, capable of continuous monitoring for up to 30 days. The platform operates through REMI Mobile software and REMI Cloud, with data review via Persyst Mobile. An add-on module, REMI Vigilenz AI for Event Detection, provides AI-powered seizure event detection with confidence scoring. A secondary product line called Epilog also exists, sharing patents with REMI. The system is FDA-cleared for both healthcare facility and ambulatory use.

Product and service3 records
1REMI Remote EEG Monitoring System
CategoryWireless EEG Monitoring Hardware/Platform
Description

A wireless, wearable EEG monitoring platform consisting of 4 single-use disposable sensors (8 electrodes creating a 10-channel montage) that capture and transmit brain electrical activity for up to 30 days. FDA-cleared for in-hospital and ambulatory use in adult and pediatric patients (1+ years), enabling continuous seizure monitoring with remote neurologist review via Persyst Mobile integration. Targets hospitals, emergency rooms, ICUs, and ambulatory/outpatient settings.

2REMI Vigilenz AI for Event Detection
CategoryAI Software Module / Medical Device Software
Description

FDA-cleared AI-powered analysis module for the REMI system that automatically identifies potential electrographic seizure activity within EEG records. Annotates EEG recordings with detected events along with confidence levels (Very High 95-100%, High 80-94%, Moderate 50-79%, Low 0-49%) and duration. Validated at 86.2% event-level sensitivity and 0.162 false alarms per hour. Indicated for adult and pediatric patients (6+ years).

3Epilog
CategoryWireless EEG Sensor Product Line
Description

A wireless EEG sensor product line for seizure monitoring, covered by the same patent portfolio as REMI (US11,633,139; US11,638,551). Includes Epilog sensors, stickers, and config software. Components may be sold individually or as part of a system.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeTechnology or Integration
Description

Integration partnership where REMI transmits data to Persyst Mobile, the most common EEG monitoring platform, for remote review by healthcare professionals.

Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

Third-party security and compliance attestation provider. Epitel achieved SOC 2 Type 2 + HIPAA + GDPR Compliance Attestation via Prescient Assurance.

3Health-ISAC
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Active member of Health-ISAC, a community committed to cybersecurity threat identification and mitigation in healthcare through information sharing.

epitel.com
Strategic tierCoreTypeTechnology or Integration
Description

AWS is a subprocessors providing infrastructure hosting for Epitel's product suite.

Strategic tierMinorTypeImplementation/ SI/ Consulting Partner
Description

Penetration testing provider used by Epitel for testing hardware and software components including server and cloud environments.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Wearable biosensor company with FDA-cleared Embrace device for epilepsy seizure detection (consumer/ambulatory). Comparable on wearable neurological monitoring form factor and seizure detection use case, though positioned in consumer/ambulatory rather than hospital settings.

TypeEmerging player
Description

Neurotechnology company focused on continuous EEG monitoring and AI analytics for ICU and inpatient neurology. Comparable on wireless/neuromonitoring + AI seizure detection stack; competes in the same in-hospital critical care segment as REMI.

TypeBroad incumbent
Description

Large-cap medtech incumbent with a Neurology portfolio (e.g., BrainSense, StealthStation) and broader patient monitoring business. Comparable on neurology buyer access and adjacent neuro-monitoring workflows; potential acquirer or strategic partner given Epitel's complementary wireless EEG capability.

TypeBroad incumbent
Description

Large patient monitoring and pulse oximetry incumbent with a growing neuroscience/EEG portfolio (via SedLine, O3 regional oximetry, and related acquisitions). Comparable as a broad incumbent building into continuous neurological/physiological monitoring in hospital settings; significant overlap on ICU monitoring buyer relationships.

TypeDirect peer
Description

Australian-based neurodiagnostics and sleep medical device manufacturer offering EEG systems for clinical and research use. Comparable in EEG monitoring product category and target neurology customer base; competes in ambulatory and in-hospital EEG segments that overlap directly with REMI's positioning.

TypeDirect peer
Description

Established neurodiagnostics medical device company offering EEG systems (wired and wireless) and related consumables for hospitals and neurology clinics. Directly comparable product category (clinical EEG) with much broader portfolio and larger sales force; serves the same hospital neurology, ICU, and ambulatory EEG buyers as Epitel.

TypeDirect peer
Description

Developer of a rapid-response EEG system (Ceribell EEG Headband + cloud seizure detection AI) for hospital ICUs and emergency departments. Closest direct competitor to Epitel — both target rapid EEG initiation in critical care without an EEG technician, with AI-powered seizure detection. Highly relevant for head-to-head hospital sales comparisons.

TypeDirect peer
Description

Publicly-traded neuro device company with the RNS System for closed-loop responsive neurostimulation in epilepsy. Comparable end market (epilepsy care) and customer (neurologists/epileptologists); different mechanism (implanted device) but same disease and clinician call point.

TypeEmerging player
Description

Emerging neurodiagnostics company focused on remote EEG monitoring and home-based brain monitoring services. Direct overlap with REMI's ambulatory/home seizure monitoring use case; smaller scale but targets the same outpatient neurology and rural-access segments.

TypeDirect peer
Description

Neurological wearable and EEG analytics company with products spanning clinical and consumer neuro-monitoring. Overlaps with Epitel on wireless EEG hardware and AI-driven neurological signal analysis; relevant for competitive dynamics in ambulatory/wearable neurotech.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights8 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Epitel

Neurological Monitoring Devicesepitel.com

Epitel is a privately held digital health company that develops the REMI wireless EEG monitoring system and REMI Vigilenz AI for seizure detection, serving emergency rooms, ICUs, hospitals, and ambulatory patients in the U.S. neurology market.

What Epitel does

Epitel is a privately held digital health company headquartered in Salt Lake City, Utah, that develops wireless EEG (electroencephalography) monitoring systems for seizure detection in neurological care. The company's core product, the REMI Remote EEG Monitoring System, is a truly wireless, wearable platform consisting of four single-use, disposable sensors with eight electrodes forming a 10-channel montage, capable of continuous EEG capture for up to 30 days in both hospital and ambulatory settings. REMI is FDA-cleared for adult and pediatric patients (1+ years) and transmits data through REMI Mobile software to a secure REMI Cloud for review on Persyst Mobile, the dominant EEG viewing platform used by neurologists.

The company's AI offering, REMI Vigilenz AI for Event Detection, is an FDA-cleared software module (2024) that automatically identifies potential electrographic seizure activity in REMI EEG recordings and annotates detected events with tiered confidence levels (Very High 95-100% through Low 0-49%). The model was trained on a clinical validation dataset of 50 patient records covering over 2,600 hours of EEG activity and 87 known seizures, achieving 86.2% event-level sensitivity and 0.162 false alarms per hour in validation. The company holds 11 active US patents covering both REMI and a secondary Epilog sensor product line, and operates with SOC 2 Type 2 + HIPAA + GDPR compliance.

Epitel generates revenue through a combination of hardware sales (single-use disposable sensors) and recurring subscription software (REMI Vigilenz AI), with the system reimbursable via preexisting codes. The company targets emergency rooms, intensive care units, and hospitals for rapid EEG initiation in critical care use cases, and ambulatory/outpatient settings for extended seizure monitoring (addressing the limitations of traditional 72-hour wired EEG). The company sells directly to healthcare facilities through enterprise sales and has raised approximately $15.6 million in venture capital ($12.5M Series A in February 2022 plus a ~$3.12M exempt offering in March 2025), with notable investors including Genoa Ventures, Catalyst Health Ventures, OSF Ventures, Dexcom Ventures, MedMountain Ventures, SLC Angels, and Wavemaker 360 Health. Earlier funding included NIH grants totaling approximately $7.8 million and a $100,000 Ideaship investment.

Epitel firmographics

Firmographics
Name
Epitel
Legal name
Epitel, Inc.
Website
https://epitel.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
51–100 employees
Short description
Epitel is a privately held digital health company that develops the REMI wireless EEG monitoring system and REMI Vigilenz AI for seizure detection, serving emergency rooms, ICUs, hospitals, and ambulatory patients in the U.S. neurology market.
Ownership category
akta.pro rank

Epitel industry classification

Industry
Product category
Neurological Monitoring Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)
SIC
Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHACAE
Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
SECONDARYHLALAGAC
Neurology Telemedicine Platforms
Healthcare & Life Sciences/Telehealth Platforms/Specialty Telemedicine Platforms (e.g., dermatology, cardiology, neurology)
SECONDARYHLACAPAI
Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring

Keywords

  • Wireless EEG monitoring
  • Seizure detection devices
  • Wearable neurological sensors
  • Medical device AI
  • Ambulatory EEG systems

Where Epitel is headquartered

Location

Headquarters

HQ city
Salt Lake City
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Epitel business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. REMI EEG Monitoring System: Sale of wireless EEG monitoring system including sensors and software. Sensors are single-use, disposable, and wearable. The system is reimbursable using preexisting codes.
  2. REMI Vigilenz AI Software: AI-powered event detection software for EEG analysis. FDA-cleared as medical device software that provides notifications to medical professionals.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

Epitel product offering

Product offering

Core offering

Epitel designs, manufactures, and sells the REMI Remote EEG Monitoring System, a truly wireless wearable EEG platform consisting of 4 single-use disposable sensors that capture brain electrical activity and wirelessly transmit data via the REMI Mobile app and REMI Cloud. The system is FDA-cleared for use in both healthcare facilities (hospitals, ERs, ICUs) and ambulatory settings in adult and pediatric patients (1+ years), supporting monitoring for up to 30 days. The company also offers REMI Vigilenz AI for Event Detection, an FDA-cleared AI software module that automatically identifies potential electrographic seizure activity within EEG recordings and provides tiered confidence-level annotations.

Product overview

Epitel offers a wireless EEG monitoring platform centered on the REMI Remote EEG Monitoring System, a truly wireless wearable solution for seizure detection. The core REMI system consists of 4 disposable sensors with 8 electrodes creating a 10-channel montage, capable of continuous monitoring for up to 30 days. The platform operates through REMI Mobile software and REMI Cloud, with data review via Persyst Mobile. An add-on module, REMI Vigilenz AI for Event Detection, provides AI-powered seizure event detection with confidence scoring. A secondary product line called Epilog also exists, sharing patents with REMI. The system is FDA-cleared for both healthcare facility and ambulatory use.

Differentiator

Problem solved

Functional benefit

Brands

  • REMI: Wireless EEG monitoring system for seizure detection in healthcare facilities and ambulatory settings
  • REMI Vigilenz AI
  • Epilog

Products and services

  • REMI Remote EEG Monitoring System A wireless, wearable EEG monitoring platform consisting of 4 single-use disposable sensors (8 electrodes creating a 10-channel montage) that capture and transmit brain electrical activity for up to 30 days. FDA-cleared for in-hospital and ambulatory use in adult and pediatric patients (1+ years), enabling continuous seizure monitoring with remote neurologist review via Persyst Mobile integration. Targets hospitals, emergency rooms, ICUs, and ambulatory/outpatient settings.
  • REMI Vigilenz AI for Event Detection FDA-cleared AI-powered analysis module for the REMI system that automatically identifies potential electrographic seizure activity within EEG records. Annotates EEG recordings with detected events along with confidence levels (Very High 95-100%, High 80-94%, Moderate 50-79%, Low 0-49%) and duration. Validated at 86.2% event-level sensitivity and 0.162 false alarms per hour. Indicated for adult and pediatric patients (6+ years).
  • Epilog A wireless EEG sensor product line for seizure monitoring, covered by the same patent portfolio as REMI (US11,633,139; US11,638,551). Includes Epilog sensors, stickers, and config software. Components may be sold individually or as part of a system.

Quantifiable outcome

  • 86.2% event-level sensitivity and 0.162 false alarms per hour in clinical validation
  • +3 more outcomes

Companies that use Epitel

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Epitel technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability2 records

Feature4 records

Epitel partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • Persyst MobilecoreTechnology or IntegrationIntegration partnership where REMI transmits data to Persyst Mobile, the most common EEG monitoring platform, for remote review by healthcare professionals.
  • Prescient AssurancecoreImplementation/ SI/ Consulting PartnerThird-party security and compliance attestation provider. Epitel achieved SOC 2 Type 2 + HIPAA + GDPR Compliance Attestation via Prescient Assurance.
  • Health-ISACminorStrategic or Co-development PartnerActive member of Health-ISAC, a community committed to cybersecurity threat identification and mitigation in healthcare through information sharing.
  • Amazon Web ServicescoreTechnology or IntegrationAWS is a subprocessors providing infrastructure hosting for Epitel's product suite.
  • CobaltminorImplementation/ SI/ Consulting PartnerPenetration testing provider used by Epitel for testing hardware and software components including server and cloud environments.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Epitel competitors and assessment

Company assessment

Emerging players

  • Empatica: Wearable biosensor company with FDA-cleared Embrace device for epilepsy seizure detection (consumer/ambulatory). Comparable on wearable neurological monitoring form factor and seizure detection use case, though positioned in consumer/ambulatory rather than hospital settings.
  • iCE Neurosystems (now Beacon Biosignals): Neurotechnology company focused on continuous EEG monitoring and AI analytics for ICU and inpatient neurology. Comparable on wireless/neuromonitoring + AI seizure detection stack; competes in the same in-hospital critical care segment as REMI.
  • Stratus Neuro: Emerging neurodiagnostics company focused on remote EEG monitoring and home-based brain monitoring services. Direct overlap with REMI's ambulatory/home seizure monitoring use case; smaller scale but targets the same outpatient neurology and rural-access segments.

Broad incumbents

  • Medtronic (Neurology / Patient Monitoring): Large-cap medtech incumbent with a Neurology portfolio (e.g., BrainSense, StealthStation) and broader patient monitoring business. Comparable on neurology buyer access and adjacent neuro-monitoring workflows; potential acquirer or strategic partner given Epitel's complementary wireless EEG capability.
  • Masimo: Large patient monitoring and pulse oximetry incumbent with a growing neuroscience/EEG portfolio (via SedLine, O3 regional oximetry, and related acquisitions). Comparable as a broad incumbent building into continuous neurological/physiological monitoring in hospital settings; significant overlap on ICU monitoring buyer relationships.

Direct peers

  • Compumedics: Australian-based neurodiagnostics and sleep medical device manufacturer offering EEG systems for clinical and research use. Comparable in EEG monitoring product category and target neurology customer base; competes in ambulatory and in-hospital EEG segments that overlap directly with REMI's positioning.
  • Natus Medical: Established neurodiagnostics medical device company offering EEG systems (wired and wireless) and related consumables for hospitals and neurology clinics. Directly comparable product category (clinical EEG) with much broader portfolio and larger sales force; serves the same hospital neurology, ICU, and ambulatory EEG buyers as Epitel.
  • Ceribell: Developer of a rapid-response EEG system (Ceribell EEG Headband + cloud seizure detection AI) for hospital ICUs and emergency departments. Closest direct competitor to Epitel — both target rapid EEG initiation in critical care without an EEG technician, with AI-powered seizure detection. Highly relevant for head-to-head hospital sales comparisons.
  • NeuroPace: Publicly-traded neuro device company with the RNS System for closed-loop responsive neurostimulation in epilepsy. Comparable end market (epilepsy care) and customer (neurologists/epileptologists); different mechanism (implanted device) but same disease and clinician call point.
  • Wave Neuroscience: Neurological wearable and EEG analytics company with products spanning clinical and consumer neuro-monitoring. Overlaps with Epitel on wireless EEG hardware and AI-driven neurological signal analysis; relevant for competitive dynamics in ambulatory/wearable neurotech.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights8 records

Customer concentration

Epitel social profiles

Digital presence

Epitel compliance and trust

Trust signal

Compliance3 records

Epitel financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Epitel leadership team

Management profile

Number of profiles

Profiles10 records

Epitel funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Epitel M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Epitel

What does Epitel do?

Epitel designs, manufactures, and sells the REMI Remote EEG Monitoring System, a truly wireless wearable EEG platform consisting of 4 single-use disposable sensors that capture brain electrical activity and wirelessly transmit data via the REMI Mobile app and REMI Cloud. The system is FDA-cleared for use in both healthcare facilities (hospitals, ERs, ICUs) and ambulatory settings in adult and pediatric patients (1+ years), supporting monitoring for up to 30 days. The company also offers REMI Vigilenz AI for Event Detection, an FDA-cleared AI software module that automatically identifies potential electrographic seizure activity within EEG recordings and provides tiered confidence-level annotations.

Is Epitel a public or private company?

Epitel is a private company. It is classified as venture growth investor backed and is currently operating.

When was Epitel founded?

Epitel was founded in 2014. It employs 51 to 100 people.

Where is Epitel based?

Epitel is headquartered in Salt Lake City, United States, in the North America region.

How does Epitel make money?

Two revenue lines are on record. REMI EEG Monitoring System is the primary driver. The others are REMI Vigilenz AI Software.

Who are Epitel's main competitors?

Emerging players on record are Empatica, iCE Neurosystems (now Beacon Biosignals) and Stratus Neuro. Broad incumbents are Medtronic (Neurology / Patient Monitoring) and Masimo. Direct peers are Compumedics, Natus Medical, Ceribell, NeuroPace and Wave Neuroscience.

Does Epitel have an API?

No public API is recorded for Epitel.

What industry is Epitel in?

Epitel's product category is Neurological Monitoring Devices. Its primary akta.pro industry code is HLAHACAE, Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables), with a secondary code of HLALAGAC, Neurology Telemedicine Platforms. Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PrwebStratus Partners with Epitel to Expand EEG Access to Patients with Seizure DisordersStratus announced a new distribution agreement with Epitel to include the REMI Remote EEG Monitoring System in its portfolio of electroencephalography services. This partnership aims to broaden patient access to critical EEG diagnostics, particularly for those with infrequent seizures or in underserved areas, by leveraging Stratus' national clinical infrastructure and technologist network.PrwebINVI MindHealth and Epitel Bring 24-Hour EEG Brain Monitoring to Veteran Mental Health ResearchINVI MindHealth has selected Epitel as the EEG data collaborator for its ARPA-H-funded EVIDENT program aimed at veteran mental health research. The partnership involves veterans wearing Epitel's REMI EEG sensors to provide continuous, 24-hour brain activity data before, during, and after behavioral health interventions.Tracxn2026 Funding Rounds & List of InvestorsThe article presents a structured list of funding rounds for the company Epitel, detailing dates, amounts, and investor information. Key events include a Series B round on July 28, 2026, and multiple grant awards from HHS in 2025. The data also covers earlier seed and series A investments involving entities such as Ideaship and OSF HealthCare.HIT ConsultantEpitel Closes $26M to Commercialize REMI Remote EEG PlatformEpitel, Inc. closed a $26M Series B funding round co-led by Catalyst Health Ventures and Genoa Ventures to expand its REMI Remote EEG Monitoring System. The funding aims to address the access gap in EEG diagnostic capacity, particularly for the 9.2 million Americans experiencing seizures annually, of whom 40% lack basic EEG access. Epitel's REMI platform allows for continuous brain activity monitoring at home with AI-assisted event detection, improving diagnostic efficiency for neurologists.Medical BuyerEpitel raises USD 26M in Series B roundEpitel, Inc. announced the closing of a $26 million Series B financing round co-led by Catalyst Health Ventures and Genoa Ventures, with participation from new and existing investors. The funding will support market expansion of the company's REMI Remote EEG Monitoring System, which provides wireless, wearable brain monitoring with AI-driven seizure detection for extended periods outside hospital settings. With this capital, Epitel plans to expand its commercial field team to increase access to neurological care, particularly for the estimated 40 percent of Americans who lack access to EEG testing.Digital Health NewsEpitel Raises $26 Mn to Expand AI-Powered Wireless EEG MonitoringUtah-based digital health startup Epitel has raised $26 million in a Series B funding round co-led by Catalyst Health Ventures and Genoa Ventures to expand its AI-powered wireless EEG monitoring technology across the United States. The funding will strengthen Epitel's commercial operations and increase adoption of its REMI platform among healthcare providers for patients with suspected seizures. The wearable REMI system, which has received five FDA 510(k) clearances since 2021, uses cloud-connected sensors to continuously record brain activity at home for several days or weeks.Utah BusinessEpitel raises $26M to expand wireless EEG monitoring – Utah BusinessEpitel, Inc. closed a $26 million Series B funding round led by Catalyst Health Ventures and Genoa Ventures to expand commercial access to its wireless EEG monitoring system, REMI. The capital will be used to grow sales teams and deploy the technology in ambulatory and at-home settings, following recent FDA clearance for patients as young as one year old. This expansion aims to address the significant gap in EEG capacity among U.S. hospitals and improve diagnosis for millions of Americans with seizure disorders.Pulse 2.0Epitel Raises $26 Million Series B To Expand Wireless Remote EEG MonitoringEpitel raised $26 million in Series B financing to expand its wireless REMI EEG monitoring system. The company will use the funds to broaden commercial availability and support provider adoption, targeting seizure diagnosis and ambulatory care. It plans to build a dedicated field team to introduce REMI to more hospitals and practices.FinancialContent Business PageEpitel Secures $26 Million Series B to Expand Remote Wireless EEG MonitoringEpitel, Inc., a digital health company specializing in AI-driven wireless brain health technologies, announced the closing of a $26 million Series B financing round co-led by Catalyst Health Ventures and Genoa Ventures. The funding will support commercial expansion of the REMI Remote EEG Monitoring System, the first fully wireless FDA-cleared EEG system, which addresses a significant gap in neurological care with 40 percent of Americans lacking access to EEG despite 9.2 million experiencing seizures annually. The company plans to use the capital to scale commercial infrastructure, accelerate provider adoption, and expand ambulatory market access, including for patients as young as one year old.Mpo-magEpitel Lands $26M Series B for Remote EEG ExpansionEpitel closed a $26 million Series B co-led by Catalyst Health Ventures and Genoa Ventures. The funding will expand its REMI remote EEG system for seizure detection and diagnosis, targeting patients as young as one year old. The company aims to grow commercial infrastructure and provider adoption.